Evidence map›Paper›PMID 31528180›Full record

ReviewImmunity & ageing : I & A2019

Immunosenescence and human vaccine immune responses.

Stephen N Crooke, Inna G Ovsyannikova, Gregory A Poland, Richard B Kennedy

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunity & ageing : I & A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 339 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
339citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

339 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. TFAM Dependent Mitochondrial Fitness Limits CD8bioRxiv : the preprint server for biology · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

279 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephen N CrookeMayo Clinic Vaccine Research Group, Mayo Clinic, Guggenheim Building 611D, 200 First Street SW, Rochester, MN 55905 USA.
Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Mayo Clinic, Guggenheim Building 611D, 200 First Street SW, Rochester, MN 55905 USA.
Gregory A PolandMayo Clinic Vaccine Research Group, Mayo Clinic, Guggenheim Building 611D, 200 First Street SW, Rochester, MN 55905 USA.
Richard B KennedyMayo Clinic Vaccine Research Group, Mayo Clinic, Guggenheim Building 611D, 200 First Street SW, Rochester, MN 55905 USA.

Funding

Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune ProfilingU01AI089859 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2010 to 2015
$33.8M
Systems Biology of Mumps Vaccine ResponseR01AI138965 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B · 2018 to 2022
$3.9M
Transcriptomic Signatures of Influenza Vaccine ResponsesR01AI132348 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B, POLAND, GREGORY A. · 2018 to 2022
$3.9M
Genetic Markers of Long-Term Mumps Vaccine ImmunityR01AI127365 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B · 2016 to 2020
$3.6M
NIAID NIH HHS R01 AI127365NIAID NIH HHS R01 AI132348NIAID NIH HHS R01 AI138965NIAID NIH HHS U01 AI089859
6 · The paper itself

Abstract

The age-related dysregulation and decline of the immune system-collectively termed "immunosenescence"-has been generally associated with an increased susceptibility to infectious pathogens and poor vaccine responses in older adults. While numerous studies have reported on the clinical outcomes of infected or vaccinated individuals, our understanding of the mechanisms governing the onset of immunosenescence and its effects on adaptive immunity remains incomplete. Age-dependent differences in T and B lymphocyte populations and functions have been well-defined, yet studies that demonstrate direct associations between immune cell function and clinical outcomes in older individuals are lacking. Despite these knowledge gaps, research has progressed in the development of vaccine and adjuvant formulations tailored for older adults in order to boost protective immunity and overcome immunosenescence. In this review, we will discuss the development of vaccines for older adults in light of our current understanding-or lack thereof-of the aging immune system. We highlight the functional changes that are known to occur in the adaptive immune system with age, followed by a discussion of current, clinically relevant pathogens that disproportionately affect older adults and are the central focus of vaccine research efforts for the aging population. We conclude with an outlook on personalized vaccine development for older adults and areas in need of further study in order to improve our fundamental understanding of adaptive immunosenescence.

Indexed as

Adaptive immunityAgingB cellImmune responseImmunosenescenceT cellVaccination

Identifiers

PMID31528180
PMCPMC6743147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.